Especially TIGIT, which is expressed on tumor-infiltrating cytotoxic T cells in multiple malignancies and its ligand CD155, often expressed by tumor-infiltrating myeloid cells and upregulated on cancer cells, provide a promising target to overcome the local suppression of immune surveillance. Here, TIGIT is linked to neoplasm.